InVivo Therapeutics Holdings Corp. (NVIV) Sets Yearly Low on Jun, 29

June 29, 2018 - By Don Salinas

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Corporate Logo

Today InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) with $1.73 price per share, touched 1-year low with $1.63 PT or 6.00 % below. On Jun, 29 the 1-year low was announced by The company has $3.52 million market cap. $211,440 less could be NASDAQ:NVIV valuation at $1.63 share price.

The stock decreased 1.14% or $0.02 during the last trading session, reaching $1.73.Currently InVivo Therapeutics Holdings Corp. is downtrending after 86.50% change in last June 29, 2017. NVIV has also 58,361 shares volume. NVIV underperformed the S&P500 by 99.07%.

On August, 14 is expected InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)’s earnings report, as reported by Faxor. Analysts have anticipation on stock’s EPS of $-3.25. That’s up 35.00 % from last year’s $-5 EPS. After $-3.34 EPS was revealed last quarter, analysts now see EPS growth of -2.69 % for InVivo Therapeutics Holdings Corp..

For more InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) news brought out recently go to:,,, or The titles are as follows: “40 Biggest Movers From Friday” brought out on June 18, 2018, “InVivo Therapeutics Announces Closing of $15.2 Million Public Offering, Including the Exercise of Underwriter’s …” on June 25, 2018, “Mid-Morning Market Update: Markets Open Lower; Kroger Earnings Beat Expectations” with a publish date: June 21, 2018, “50 Biggest Movers From Yesterday” and the last “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” with publication date: June 21, 2018.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries .The firm is valued at $3.52 million. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI.Currently it has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: